First patient enrolled in phase II study of novel cystic fibrosis treatment, BI-1265162 Oct. 17, 2019 No Comments
Enterprise Therapeutics receives funding for development of novel CF therapy Oct. 17, 2019 No Comments
Tezepelumab reduces activation of matrix remodeling and inflammatory pathways Oct. 9, 2019 No Comments
MTPS-9579A dose-dependently inactivates airway tryptase for the treatment of asthma Oct. 9, 2019 No Comments
Inhaled AZD-8154 demonstrates superior pharmacokinetics over intravenous administration Oct. 8, 2019 No Comments
RSS